MedTrace Logo

Anti-inflammatory Effects of Simvastatin

NCT04638400 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-11-08

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to determine which of the two ingredients of Vytorin (Simvastatin or Ezetimibe) is responsible for the anti-inflammatory effects of Vytorin

Conditions

Interventions

DRUG

Simvastatin 40mg

Simvastatin administered daily for 6 weeks

DRUG

Ezetimibe 10mg

Ezetimibe administered daily for 6 weeks

Sponsors & Collaborators

  • paresh Dandona

    lead OTHER

Principal Investigators

  • Paresh Dandona, MD, PhD · Distinguished Professor of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2021-08-01
Completion
2021-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04638400 on ClinicalTrials.gov